927800-55-3

Basic information

• Product Name: 4-CHLORO-6-TRIFLUOROMETHOXYQUINOLINE
• Synonyms: 4-CHLORO-6-TRIFLUOROMETHOXYQUINOLINE
• CAS NO: 927800-55-3
• Molecular Formula: C₁₀H₅ClF₃NO
• Molecular Weight: 247.6
• Mol File: 927800-55-3.mol

Chemical Properties

• Boiling Point: 259.4°C at 760 mmHg
• Flash Point: 110.7°C
• Appearance: /
• Density: 1.464g/cm³
• Vapor Pressure: 0.0211mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: 2-8°C
• PKA: 2.55±0.16(Predicted)
• CAS DataBase Reference: 4-CHLORO-6-TRIFLUOROMETHOXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-TRIFLUOROMETHOXYQUINOLINE(927800-55-3)
• EPA Substance Registry System: 4-CHLORO-6-TRIFLUOROMETHOXYQUINOLINE(927800-55-3)

Safety Data

• Hazardous Substances Data: 927800-55-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H5ClF3NO/c11-8-3-4-15-9-2-1-6(5-7(8)9)16-10(12,13)14/h1-5H

Upstream product

• 461-82-5 4-(trifluoromethoxy)aniline 
• 1071540-59-4 5-[(4-(trifluoromethoxy)phenylamino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 175203-87-9 6-(trifluoromethoxy)quinolin-4-ol 

Relevant articles and documents

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

DUAL MOLECULES CONTAINING A PEROXIDE DERIVATIVE, THEIR SYNTHESIS AND THERAPEUTIC USES

The invention concerns dual molecules corresponding to formula (I): in which: A represents a molecular residue with antimalarial activity of formula (IIa) or (IIIa) or a residue facilitating bioavailability; B represents a cycloalkyl group potentially substituted, or B represents a bi- or tricyclic group capable of being substituted, or B represents 2 cycloalkyl groups linked together through either a single bond or an alkylene chain; m and n represent independently of one another 0, 1 or 2; R5 represents a hydrogen atom, an alkyl, cycloalkyl or C1-3-alkylene-cycloakyl group; Z1 and Z2 represent an alkyl radical, the group Z1+Z2+Ci+Cj representing a mono- or polycyclic structure, with one of the Z1 or Z2 being able to represent a single bond; R1 and R2, identical or different, represent a hydrogen atom or a functional group capable of increasing hydrosolubility; Rx and Ry forming together a cyclic peroxide including 4 to 8 links and including 1 or 2 additional oxygen atoms in the cyclic structure, possibly substituted by one or more R3 groups; as a base or a salt to be added to an acid, as a hydrate or solvate, in racemic form, isomers and their mixtures, in addition to their diasteroisomers and their mixtures. Preparation method and use as medications with antimalarial activity.

Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities

A simple two-step synthesis method was used to make 51 B-ring-substituted 4-hydroxyquinolines allowing analysis of the effect of ring substitutions on inhibition of growth of chloroquine sensitive and resistant strains of Plasmodium falciparum, the dominant cause of malaria morbidity. Substituted quinoline rings other than the 7-chloroquinoline ring found in chloroquine were found to have significant activity against the drug-resistant strain of P. falciparum W2.